Spondylolisthesis Clinical Trial
— DSSOfficial title:
A Postmarket Surveillance Study of the Paradigm Spine Dynamic Stabilization System(DSS)
Verified date | February 2020 |
Source | Paradigm Spine |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of the Post-Market Surveillance study is to evaluate safety.
Status | Terminated |
Enrollment | 1 |
Est. completion date | September 2016 |
Est. primary completion date | September 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years to 85 Years |
Eligibility |
Inclusion Criteria: - Patient is skeletally mature (21-85 years old). - Patient has degenerative spondylolisthesis (Grade 1-3) with objective evidence of neurologic impairment, kyphosis, and/or failed previous fusion (pseudarthrosis) at index level. - Capable and willing to comply with the requirements unique to the study, adhere to the post-operative treatment and management program, and return for required follow-up examinations. - Surgeon has determined that DSS™ System is an appropriate treatment for the patient without regard to the study. Exclusion Criteria: - The need for interbody cages, allograft, or any other assistance during surgery. Device is only to be used with autograft per FDA approved indications. - Any medical, mental or surgical condition precluding the potential benefit of spinal surgery or surgery in general. - Acute or chronic systemic, spinal or localized infections. - Active, severe systemic and metabolic diseases. - Obesity defined as Body Mass Index > 35. - Subject is pregnant or interested in becoming pregnant in the next 36 months. - Dependency on pharmaceutical drugs, drug abuse, or alcoholism. - Lack of patient cooperation. - Foreign body sensitivity to the implant material. - Degenerative scoliosis greater than 25 degrees. - Grade 4 degenerative spondylolisthesis (>75% slip). - Significant osteopenia A screening questionnaire for osteopenia, SCORE (Simple Calculated Osteoporosis Risk Estimation), will be used to screen patients who require a DEXA bone mineral density measurement. If DEXA is required*, exclusion will be defined as a DEXA bone density measured T score of = -1.0 (The World Health Organization definition of osteopenia). - Soft tissue deficit not allowing wound closure. - Congenital abnormalities, tumors or other conditions that would prevent secure component fixation that has the potential to decrease the useful life of the device. - Inadequate pedicles or vertebral body geometry of the thoracic, lumbar and sacral vertebrae. - Bony lumbar spinal stenosis not related to the primary degenerative spondylolisthesis indication. - Pars defect. - Clinically compromised vertebral bodies at affected level due to current or past trauma. - Prisoner or ward of the state. - Currently in litigation regarding a spinal condition. - Known allergy to titanium, titanium alloys, CoCrMo, polyethylene or MR contrast agents. - Is currently involved in a study of another investigational product for similar purpose. |
Country | Name | City | State |
---|---|---|---|
United States | University of California, Davis Medical Center | Sacramento | California |
Lead Sponsor | Collaborator |
---|---|
Paradigm Spine | Musculoskeletal Clinical Regulatory Advisers |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants Who Have an Incidence of Serious or Device Related Adverse Events Due to Device or Procedure. | The safety endpoint is defined as the incidence of serious or device related adverse events attributable to the device or procedure. Reoperations, revisions or removals of the Dynamic Stabilization System (DSS) System implant will be evaluated. | 6 months | |
Secondary | Measurement of Lower Back Pain as Assessed by Visual Analog Scale | Lower back pain as measured by the Visual Analog Scale (VAS) on the scale from 0 (no pain) to 100 (worst imaginable pain) | 6 months | |
Secondary | Measurement of Right Leg Pain as Assessed by Visual Analog Scale | Right leg pain as measured by the Visual Analog Scale (VAS) on the scale from 0 (no pain) to 100 (worst imaginable pain) | 6 months | |
Secondary | Measurement of Left Leg Pain as Assessed by Visual Analog Scale | Left leg pain as measured by the Visual Analog Scale (VAS) on the scale from 0 (no pain) to 100 (worst imaginable pain) | 6 months | |
Secondary | Number of Participants With Improved Health as Measured by the EuroQOL Health Related Qualify of Life- 5 Dimensions-3 Level (EQ-5D-3L) Health Questionnaire Compared to Baseline. | The EQ-5D-3L is a standardized instrument used as a measure of health outcomes. It contains questions in 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and provides a simple descriptive profile and single index for health status preference. In addition, there is a Visual Analog Scale (VAS). The VAS is the participant's rating of their health on a scale of 0 "worst imaginable health state" to 100 "best imaginable health state". | Pre-Op, 6 weeks, 6 months, 12 months, and 24 months | |
Secondary | Assessment of Back Pain Using the Oswestry Low Back Pain Disability Index (ODI). | ODI is a questionnaire that provides information on back and the affects on managing every day life by diving questions into 10 sections. The total possible score for each section is 0-5. The scores are then converted into percentages ranging from 0% (minimal disability) to 100% (maximum possible disability). | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03883022 -
Vancomycin Powder Combined With Autogenous Bone Graft as a Prevention for Post-operative Infection for Spine Surgery
|
N/A | |
Active, not recruiting |
NCT04542577 -
PMCF Study on the Safety and Performance of PROSPACE 3D / PROSPACE 3D OBLIQUE / TSPACE 3D
|
||
Recruiting |
NCT04477447 -
PMCF Study on the Safety and Performance of CESPACE 3D
|
||
Completed |
NCT02558621 -
New Robotic Assistance System for Spinal Fusion Surgery
|
N/A | |
Completed |
NCT00405691 -
Safety and Effectiveness Study of the TOPS System, a Total Posterior Arthroplasty Implant Designed to Alleviate Pain Resulting From Moderate to Severe Lumbar Stenosis
|
Phase 3 | |
Completed |
NCT00205101 -
Clinical Outcome Study of the Triad Allograft for Posterior Lumbar Fusion
|
||
Enrolling by invitation |
NCT04204135 -
The Course of Hip Flexion Weakness Following LLIF or ALIF
|
||
Recruiting |
NCT05238740 -
Comparison of Standalone Anterior Lumbar Interbody Fusion (ALIF) L5/S1 Performed With Either rhBMP-2 or ViviGen®
|
N/A | |
Completed |
NCT02966639 -
Validation of Appropriateness Criteria for the Surgical Treatment of Lumbar Degenerative Spondylolisthesis
|
||
Completed |
NCT02931279 -
PASS OCT® Post-market Clinical Follow-up
|
||
Not yet recruiting |
NCT02805985 -
Post-market Surveillance Study of FLXfit™ TLIF Interbody Fusion Device
|
N/A | |
Active, not recruiting |
NCT02057744 -
MIS ReFRESH: Robotic vs. Freehand Minimally Invasive Spinal Surgeries
|
||
Completed |
NCT01711203 -
The Addition of a Pilates Program for Short-Term Improvements in Patients With Spondylolysis or Spondylolisthesis
|
N/A | |
Completed |
NCT00549913 -
Study of 3 Doses of NeoFuse Combined With MasterGraft Granules in Subjects Requiring Posterolateral Lumbar Fusion (PLF)
|
Phase 1/Phase 2 | |
Terminated |
NCT00254852 -
Evaluation of Radiographic and Patient Outcomes Following Lumbar Spine Fusion Using Demineralized Bone Matrix (DBM) Mixed With Autograft
|
N/A | |
Terminated |
NCT00095095 -
Lumbar Interbody Fusion Using the Telamon® Peek™ Versus the Telamon® Hydrosorb™ Fusion Device
|
Phase 4 | |
Active, not recruiting |
NCT03956537 -
PMCF Neo Pedicle Screw and Cage Systems
|
||
Recruiting |
NCT05182489 -
Adaptix RCT Evaluating Adaptix™ Versus PEEK Cages
|
N/A | |
Completed |
NCT02884440 -
Transverse Abdominis Plane Block for Anterior Approach Spine Surgery
|
Phase 2 | |
Enrolling by invitation |
NCT02958241 -
Supine vs. Upright Weight Bearing MRI in the Evaluation of Patients With Lumbar Spondylolisthesis
|
N/A |